

## Immuuntherapie: de rol van beeldvorming, *Imago* 2022-1

### Literatuurlijst

1. Martins F, Sofiya L, Sykietis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. *Nat Rev Clin Oncol*. 2019 Sep;16(9):563–80.
2. Dromain C, Beigelman C, Pozzessere C, Duran R, Digklia A. Imaging of tumour response to immunotherapy. *Eur Radiol Exp*. 2020 Jan 3;4(1):2.
3. Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Hata T, Kim YH, et al. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy. *J Thorac Oncol*. 2019 Mar;14(3):468–74.
4. Saâda-Bouazid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, et al. Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. *Ann Oncol*. 2017 Jul 1;28(7):1605–11.
5. Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med*. 2016 Nov 10;375(19):1856–67.
6. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Vol. 18, *The Lancet Oncology*. 2017. p. e143–52.
7. Ahmed FS, Dercle L, Goldmacher GV, Yang H, Connors D, Tang Y, et al. Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial. *Eur Radiol*. 2021 Apr;31(4):1853–62.
8. Tazdait M, Mezquita L, Lahmar J, Ferrara R, Bidault F, Ammari S, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. *Eur J Cancer*. 2018 Jan;88:38–47.
9. Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, et al. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. *N Engl J Med*. 2018 May 24;378(21):1976–86.
10. van Dijk N, Gil-Jimenez A, Silina K, Hendricksen K, Smit LA, de Feijter JM, et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. *Nat Med*. 2020 Dec;26(12):1839–44.
11. Anwar H, Sachpekidis C, Winkler J, Kopp-Schneider A, Haberkorn U, Hassel JC, et al. Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. *Eur J Nucl Med Mol Imaging*. 2018 Mar;45(3):376–83.
12. Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. *Ann Oncol*. 2017 Oct 1;28(10):2377–85.
13. Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, et al. Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. *JAMA Oncol*. 2018 Mar 1;4(3):374–8.

14. Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. *Clin Cancer Res*. 2016 Feb 15;22(4):886–94.
15. Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot J-M, Lambotte O, et al. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. *Eur J Cancer*. 2018 Jun;96:91–104.
16. Kalisz KR, Ramaiya NH, Laukamp KR, Gupta A. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. *Radiographics*. 2019 Nov;39(7):1923–37.
17. Das JP, Postow MA, Friedman CF, Do RK, Halpenny DF. Imaging findings of immune checkpoint inhibitor associated pancreatitis. *Eur J Radiol*. 2020 Oct;131:109250.
18. Khauli MA, An TJ, Anderson MA. Imaging Findings in Immunotherapy-related Renal Toxicity. *J Immunother* [Internet]. 2021 Oct 20; Available from: <http://dx.doi.org/10.1097/CJI.0000000000000398>
19. Carpenter KJ, Murtagh RD, Lilienfeld H, Weber J, Murtagh FR. Ipilimumab-induced hypophysitis: MR imaging findings. *AJNR Am J Neuroradiol*. 2009 Oct;30(9):1751–3.
20. Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E. FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature. *Eur J Nucl Med Mol Imaging*. 2019 Jan;46(1):238–50.
21. Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen GAMS, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. *Nat Commun*. 2018 Nov 7;9(1):4664.
22. Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. *Nat Med*. 2018 Dec;24(12):1852–8.
23. Pandit-Taskar N, Postow MA, Hellmann MD, Harding JJ, Barker CA, O'Donoghue JA, et al. First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. *J Nucl Med*. 2020 Apr;61(4):512–9.
24. Necchi A, Bandini M, Calareso G, Raggi D, Pederzoli F, Farè E, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. *Eur Urol*. 2020 May;77(5):636–43.
25. Song J, Kadaba P, Kravitz A, Hormigo A, Friedman J, Belani P, et al. Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors. *Neuro Oncol*. 2020 Nov 26;22(11):1658–66.
26. Karayama M, Yoshizawa N, Sugiyama M, Mori K, Yasui H, Hozumi H, et al. Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer. *Lung Cancer*. 2020 May;143:47–54.
27. Lau D, McLean MA, Priest AN, Gill AB, Scott F, Patterson I, et al. Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma. *J Immunother Cancer* [Internet]. 2021 Sep;9(9). Available from: <http://dx.doi.org/10.1136/jitc-2021-003125>

28. Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Călin AM, Delli Pizzi A, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. *Ann Oncol.* 2019;30(6):998–1004.
29. Zhang C, de A F Fonseca L, Shi Z, Zhu C, Dekker A, Bermejo I, et al. Systematic review of radiomic biomarkers for predicting immune checkpoint inhibitor treatment outcomes. *Methods.* 2021 Apr;188:61–72.
30. Bodalal Z, Wamelink I, Trebeschi S, Beets-Tan RGH. Radiomics in immuno-oncology. *Immuno-Oncology and Technology.* 2021 Mar 1;9:100028.